Condition: Leptomeningeal Metastasis · Intrathecal Drug Delivery · Sponsor: Guangzhou Medical University
Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant tumors. This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal PD-1/VEGF bispecific antibody plus pemetrexed in patients with leptomeningeal metastasis.
This description comes directly from the study's public registry record.
Zhenyu Pan, PhD, MD · +8618718178286 · dr-zypan@163.com
Guozi Yang, PhD,MD · +8615804302755 · 2023621057@gzhmu.edu.cn
Always discuss trial participation with your own doctor first.
| The Affiliated Huizhou Hospital, Guangzhou Medical University | Huizhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06809517